Pharmacogenetics and Pharmacogenomics

Pharmacogenetics refers to how variation in one single gene influences the response to a single drug and Pharmacogenomics refers to how all of the genes (the genome) can influence responses to drugs. The general feature of these diverse lesions is that two nucleotides on opposite strands are joined covalently. Mutagenicity and carcinogenicity are clearly correlated. Understanding the specificity of mutagens in bacteria has led to the direct implication of certain environmental mutagens in the causation of human cancers Recent advances in DNA repair are DNA inter strand cross-links (ICLs) are lesions caused by a variety of endogenous metabolites, ecological exposures, and cancer chemotherapeutic agents that have two reactive groups. The general feature of these diverse lesions is that two nucleotides on opposite strands are joined covalently. Mutagenicity and carcinogenicity are clearly correlated. The somatic mutation theory of cancer holds that these agents cause cancer by causing the mutation of somatic cells. A unique feature of inter-strand cross-links repair is that both strands of DNA must be incised to completely remove the lesion. Drug dosing guidelines accomplished in sequential steps to prevent creating multiple double-strand breaks. Understanding the specificity of mutagens in bacteria has led to the direct implication of certain environmental mutagens in the causation of human cancers.

  • Track 1-1 Cancer pharmcogenetics
  • Track 2-2 Pharmacognosy
  • Track 3-3 Pharmacology of drugs affecting vascular tone and blood pressure
  • Track 4-4 Pharmacology of the Vascular endothelium
  • Track 5-5 Recent advances in variant-disease pairs
  • Track 6-6 Drug dosing guidelines
  • Track 7-7 Mutagenecity- its implications in cancer following chemotherapy
  • Track 8-8 Pharamcogenetic approach involved in modulating cell processes
  • Track 9-9 Recent advances in DNA repair
  • Track 10-10 Methods To determine biological targeting
  • Track 11-11 Molecular epidemiology and its biomarkers
  • Track 12-12 Molecular pathological epidemiology
  • Track 13-13 Pharmacovigilance and post marketing surveillance
  • Track 14-14 Adverse event reporting system

Related Conference of Pharmaceutical Sciences